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Background: Oral anticoagulant (OAC) is proven to be more effective than antiplatelet therapy in the
secondary prevention of ischemic stroke in patients with atrial ﬁbrillation (AF). The objective of this
study was to determine the effect of age on the prescription of OAC and its actual use by neurologists for
secondary prevention among the very elderly patients with AF hospitalized for ischemic stroke.
Methods: In this prospective observational study, data from patients with ﬁrst-ever ischemic stroke and
AF were included. We reviewed the use of antithrombotic agents before stroke onset and at discharge in
patients with AF who were aged 80 years or older. We analyzed the trends of oral anticoagulation as
secondary prevention in very elderly patients and identify the reasons why anticoagulant was not
prescribed at discharge.
Results: A total of 152 patients with AF experienced ﬁrst-ever ischemic stroke. Of these, 51 patients
(33.6%) were 80 years of age, and 101 were <80 years of age. Thirteen patients died during the acute
stroke and thus were excluded from the analysis. Of 139 ischemic stroke survivors at discharge, 45 were
80 years of age and 94 were <80 years of age. For those aged 80 years, 62.2% received neither
antiplatelet nor anticoagulant agents before stroke onset. Surprisingly, only one patient (2.2%) was
treated with OAC. At discharge, only 12 patients (26.7%) aged80 years were treated with OAC compared
with those aged <80 years (48/94 [51.1%]).
Conclusion: This study suggests that OAC is underused in most of the very elderly patients despite its
proven efﬁcacy. A history of stroke did alter the trend of use of antithrombotic agents in this age group.
Copyright  2011, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
The prevalence of atrial ﬁbrillation (AF) increases dramatically
with age, from 5% in people aged 65 years and older to approxi-
mately 10% in those aged 80 years or older1. AF is a major risk factor
for stroke. The risk of stroke is increased ﬁvefold2 and is even
higher in thosewith additional cardiovascular risk factors3. Because
risk of stroke increases with age4, and strokes associated with AF
cause substantial neurologic disability or death, therefore stroke
prevention in the very elderly people with AF is of particular
importance.
Elderly patients with an ischemic stroke associated with AF are
at especially high risk for recurrent stroke with an annual rate of
more than 10%. The European Atrial Fibrillation Trial (EAFT)5Neurology, Mackay Memorial
ipei, Taiwan. Tel.: þ886 2
erest.
iwan Society of Geriatric Emergenshowed that the annual risk was 12% in controls as compared
with 4% in those treated with oral anticoagulant (OAC). The Stroke
Prevention in Atrial Fibrillation (SPAF) III trial6 conﬁrmed the
results of the EAFT. A combined analysis of the EAFT and Stroke
Prevention in Atrial Fibrillation III showed a similar beneﬁt of OAC7.
Despite the proven efﬁcacy of OAC in prevention of recurrent stroke
and the clear recommendations from the guidelines8,9 it is still
underused worldwide10e16. The aim of the present study was to
determine the effect of age and the prescribing patterns of
neurologist at discharge in very elderly patients with a recent
ischemic stroke and a known AF.
2. Methods
A prospective observational study is conducted from July 1, 2005
to June 30, 2007, in a medical center located in the northern part of
Taipei, Taiwan. Patients with an acute ﬁrst-ever ischemic stroke and
previously known or newly diagnosed AF admitted to the
neurology service were included in the study. We deﬁned stroke
using the World Health Organization deﬁnition17. Patients withcy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Baseline characteristics of the 152 patients with atrial ﬁbrillation and ﬁrst-ever
ischemic stroke
Characteristics <80 yr of age 80 yr of age
No. of patients 101 51
Agedyr (mean  SD) 68.33  9.34 85.12  3.82
Genderdn (%)
Male 53 (52.5) 17 (33.3)
Female 48 (47.5) 34 (66.7)
NIHSS (median  SD) 12 9
Risk factorsdn (%)
Hypertension 85 (84.2) 44 (86.3)
Congestive heart failure 38 (37.6) 25 (49.0)
Ischemic heart disease 41 (40.6) 17 (33.3)
Diabetes 35 (34.7) 15 (29.4)
Hyperlipidemia 40 (39.6) 9 (17.6)
Tobacco use 16 (15.8) 4 (7.8)
Functional outcome (mRS)dn (%)
mRS (0e3) 55 (54.5) 20 (39.2)
mRS (4e5) 35 (34.6) 24 (47.1)
Death 11 (10.9) 7 (13.7)
TOAST stroke subtypedn (%)
Large artery 4 (4.0) 3 (5.9)
Cardioembolic 88 (87.1) 35 (68.6)
Lacunar 9 (8.90) 13 (25.5)
OCSP stroke subtypedn (%)
TACI 30 (29.7) 16 (31.4)
PACI 41 (40.6) 14 (27.4)
POCI 21 (20.8) 8 (15.7)
LACI 9 (8.9) 13 (25.5)
LACI ¼ lacunar infarct; mRS ¼ modiﬁed Rankin Scale; NIHSS ¼ National Institute of
Health Stroke Scale; OCSP ¼ Oxfordshire Community Stroke Project; PACI ¼ partial
anterior circulation infarct; POCI ¼ posterior circulation infarct; SD ¼ standard devi-
ation; TACI ¼ total anterior circulation infarct; TOAST ¼ Trial of ORG 10172 in Acute
Stroke Treatment.
Table 2
Type of antithrombotic treatment given both for primary and secondary prevention
in very elderly patients
Treatment Primary prevention
(before stroke)
Secondary prevention
(after stroke)
n ¼ 45 n ¼ 45
OAC alone 1 (2.2%) 12 (26.7%)
Aspirin alone 7 (15.6%) 8 (17.8%)
Aspirin and other antiplatelet 0 1 (2.2%)
Ticlopidine 5 (11.1%) 4 (8.9%)
Clopidogrel 2 (4.4%) 15 (33.3%)
Other antiplatelet alone 2 (4.4%) 0
No antithrombotic treatment 28 (62.2%) 5 (11.1%)
Values are number of patients, with percentages in parentheses. The total may differ
from 100% because of rounding.
OAC ¼ oral anticoagulant.
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venous sinus thrombosis were excluded. All patients had a non-
contrast computed tomography (CT) scan at admission to exclude
intracerebral hemorrhage. Follow-up magnetic resonance imaging
or CT scan was repeated 3e5 days after the index stroke. Twelve-
lead electrocardiogram was performed in all patients during
admission and the diagnosis of AF was conﬁrmed by the cardiolo-
gist. Patient clinical features that have been associated with
increased stroke risk in patients with AF were obtained from all
available sources. These included history of hypertension, type I or
type II diabetes, ischemic heart disease, hyperlipidemia, and
congestive heart failure. Use of antithrombotic treatment before
stroke and the prescription of OAC at the time of discharge were
recorded. The use of antithrombotic agents before stroke onset was
determined from a review of medical records or inquires to
patient’s cardiologists or family physicians.We also try to identify if
there was any documentation in the medical notes explaining why
OAC was not prescribed at the time of discharge.
Baseline stroke severity was graded using the National Institute
of Health Stroke Scale18. Ischemic strokes were classiﬁed according
to the popularly used subtype classiﬁcation, the Trial of ORG 10172
in Acute Stroke Treatment criteria19. We also determined on CT or
magnetic resonance imaging scan ischemic stroke subtype and
localization as deﬁned by the Oxfordshire Community Stroke
Project20.
We used the modiﬁed Rankin Scale (mRS)21 to measure the
functional outcome at hospital discharge. Patients with a score of
0e3 were classiﬁed as no or mild-moderate dependency. Patients
with a score of 4 or 5 were classiﬁed as severe dependency. A score
of 6 denoted a severe stroke that resulted in death.
The studywas approved by the Institutional Review Board of our
hospital. Because of the nature of the study, the requirement for
informed consent was waived.
For statistical analysis, thebaseline characteristics of patients aged
80 years or <80 years were reported as percentages or mean
(median). Statistical comparisons were carried out by means of
Pearson’s c2 or unpaired t test for categorical and continuous vari-
ables, respectively. We considered a p  0.05 to be statistically
signiﬁcant.Multivariate logistic regression analysiswas performed to
identify independent predictors for medicationwith OAC at the time
ofdischarge inAFpatientswith ischemicstroke.Clinicalvariables that
were considered to be potential predictors for treatmentwith OAC as
prevention of recurrent stroke were included in the analyses. All the
statistical analyses were computed using the commercially available
software package (SPSS version 12; SPSS Inc., Chicago, IL, USA).
3. Results
There were 1,952 patients admitted with ischemic stroke during
the study period. Among these patients, 235 (12%) had AF; 83
patients diagnosed as recurrent stroke were excluded from anal-
ysis. Of the remaining 152 ﬁrst-ever ischemic stroke patients, 51
(33.6%) were 80 years of age and 101 (66.4%) were <80 years of
age. The baseline characteristics of the patients are listed in Table 1.
More than 66% of the very elderly patients were female (66.7% vs.
47.5%; p ¼ 0.025). The presence of hypertension, diabetes,
congestive heart failure, and ischemic heart disease was relatively
consistent among all patients. Very elderly patients were less likely
(17.6% vs. 39.6%; p ¼ 0.006) to have hyperlipidemia than patients
aged <80 years. Most ischemic strokes were deemed to be car-
dioembolic (81%). Thirteen patients died during the acute stroke
and thus were excluded from further analysis. Of 139 ischemic
stroke survivors at discharge, 45 were80 years of age and 94were
<80 years of age. Before stroke, 28 (62.2%) of 45 were not receiving
antithrombotic treatment, 16 (35.6%) on antiplatelet agents, andonly 1 (2.2%) on OAC. Therewas a trend toward a higher rate of OAC
and antiplatelets use at the time of discharge to prevent recurrent
stroke. Table 2 illustrates the type of antithrombotic treatment
prescribed both for primary and secondary prevention of stroke in
very elderly patients. There were signiﬁcant differences in the type
of antithrombotic treatment given at discharge between patients
aged 80 years and <80 years as shown in Table 3. The rate of the
prescription of OAC at discharge for very elderly patients was 26.7%
compared with the 51.1% found in the population younger than 80
years (p ¼ 0.003). Only eight patients were not treated with any
antithrombotic medication at discharge. Of these, ﬁve were aged
80 years (four severely disabled [mRS 5] and one died of aortic
aneurysm) and three were aged <80 years (two severely disabled
Table 3
Comparison between the type of antithrombotic treatment prescribed at discharge
among all patients
Treatment at discharge <80 yr of age 80 yr of age
(n ¼ 94) (n ¼ 45)
OAC alone 45 (47.9%) 12 (26.7%)
OAC and any antiplatelet 3 (3.2%) 0
Aspirin alone 19 (20.2%) 8 (17.8%)
Aspirin and other antiplatelet 0 1 (2.2%)
Ticlopidine 4 (4.3%) 4 (8.9%)
Clopidogrel 19 (20.2%) 15 (33.3%)
Other antiplatelet alone 1 (1.1%) 0
No antithrombotic treatment 3 (3.2%) 5 (11.1%)
Values are number of patients, with percentages in parentheses. The total may differ
from 100% because of rounding.
OAC ¼ oral anticoagulant.
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analysis, higher age, greater baseline stroke severity on the NIHSS,
and severe disability or functional dependency on the mRS were
signiﬁcantly associated with the nonprescription of OAC at
discharge (Table 4).
Wewere not able to identify reasons documented in themedical
records, whichmay explainwhy OACwas not prescribed to the very
elderly patients at the time of hospital discharge as prevention of
recurrent stroke. Given the results of the above analysis of patients,
it appears that only less than half of our patients are receiving
anticoagulation therapy for prevention of recurrent stroke at the
time of discharge.4. Discussion
Although age was not regarded as a contraindication to OAC
per se, it is one of the strongest determinants for the chance of
receiving treatment with OAC, both for primary and secondary
prevention of stroke. Our study showed that at stroke onset, only
2.2% of very elderly patients with AF and ﬁrst-ever stroke received
OAC as primary prevention. After ischemic stroke, the proportion of
very elderly patients receiving OAC as secondary prevention at
discharge was only 26.7%. Before the Birmingham Atrial Fibrillation
Treatment of the Aged Study trial22, elderly patients were signiﬁ-
cantly underrepresented in randomized trials. Participants in
earlier trials were younger than patients commonly encountered in
clinical practice, and the efﬁcacy and safety of OAC in the very
elderly is less clear. Clinicians are frequently reluctant to prescribe
anticoagulants to elderly patients with AF to prevent ﬁrst and
recurrent stroke. However, the recent publication of The Atrial
Fibrillation Investigators23 have found that above age 80, the rela-
tive and absolute beneﬁts of anticoagulants increase as patients get
older, whereas the beneﬁt of antiplatelet therapy for preventing
ischemic stroke decreased signiﬁcantly as patients aged.
Prevention of recurrent stroke in the very elderly patients is
a challenge. Elderly patients had higher levels of comorbidity, they
are at particularly high risk for recurrent stroke and are the mostTable 4
Independent predictors of oral anticoagulation at discharge in stroke patients with
atrial ﬁbrillation
OR 95%CI p
Age 80 yr 0.334 0.154e0.725 0.006
Baseline NIHSS 2.466 1.215e5.008 0.012
mRS at discharge 1.058 1.011e1.108 0.016
CI ¼ conﬁdence interval; mRS ¼ modiﬁed Rankin Scale; NIHSS ¼ National Institute
of Health Stroke Scale; OR ¼ odds ratio.likely to beneﬁt from anticoagulation. Our work demonstrated,
even for this very high-risk population, OAC is underused. The rate
of the prescription of OAC at discharge for very elderly patients was
26.7% compared with the 51.1% found in the population younger
than 80 years. Being older than 80 years appeared as one of the
major independent factors for not receiving OAC at discharge in our
present study. Similar results were found in a Swedish study16
where patients with an age 75 years or older had a chance to be
treated with OAC as secondary prevention was only a third (11.4%)
as compared with patients younger than 75 years (33.5%). In
another European study11, several factors were associated with the
nonprescription of OAC at discharge. They also found that patients
older than 75 years were less likely to be discharged under OAC.
Another independent predictor for not prescribing OAC as
secondary stroke prevention in our study was the poor functional
outcome at the time of discharge as assessed with the mRS. This is
in linewithmany observational studies, which reported that severe
disability or high functional dependencywas identiﬁed as predictor
for underuse of OAC at discharge24,25. Furthermore, the precise
beneﬁts of OAC in patients with ischemic stroke because of AF who
are left with severe disability (mRS of 3e5) are unclear because few
such patients were included in the studies5,6.
Guo et al.26 reported in their study that a previous stroke did not
alter the trend of use of OAC in patients with AF. However, data
from our study suggest that a history of stroke did alter the trend of
use of antithrombotic agents among our patients. Among these 45
very elderly patients, 28 (62.2%) were not under any antithrombotic
treatment before stroke, whereas only 5 (11.1%) were not receiving
any antithrombotic treatment as prevention of recurrent stroke.
Although not the focus of our study, we found a surprisingly
high rate of antiplatelet therapies (including aspirin and other
antiplatelet drugs) in our very elderly patients. Despite their weak
efﬁcacy in the secondary prevention of stroke in AF patients, more
than 62% of our very elderly patients were receiving antiplatelet
therapy as prevention of recurrent stroke. One possible explanation
is a lack of evidence related to the risks of OAC use in Asians10;
instead, antiplatelet agents were prescribed in these patients.
Compared with Western countries, the rate of OAC prescribing
was lower in Taiwan10. One of the reasons is the uncertainty over
the optimal treatment of elderly patients with AF still exist. Few
guidelines on the use of OAC speciﬁc for the geriatric patient
population are available. Confusion in the current guidelines8,27 is
reﬂected in clinical practice. A lower INR goal than normally used is
in fact well tolerated and effective in Chinese patients as reported in
several studies28e30. This may be attributed to differences in
thromboembolic and bleeding risks between races.
Several limitations of our study must be acknowledged. First,
the study focuses on hospitalized stroke patients in one hospital
with small number of patients eligible for analysis. The results may
be of limited generalizability. Second, as shown in this study,
almost three-quarters of the very elderly stroke patients with AF
were not on OAC at the time of hospital discharge. The reasons for
not prescribing OAC were not clearly documented in most of the
medical notes. Some physicians may have deliberately avoided
OAC, whereas others may have overlooked prophylaxis. Third, we
did not differentiate between paroxysmal (or intermittent) and
chronic (or sustained) AF. However, this should not inﬂuence our
results as the rates of stroke are surprisingly similar in both
circumstances and many elderly patients with recurrent parox-
ysmal AF beneﬁt substantially from anticoagulation31,32.
In conclusion, our study identiﬁes an important underuse of
OAC in very elderly stroke patients with AF. Assessing the beneﬁt-
risk ratio of anticoagulation is indeed a challenging issue in the very
elderly patients. Increased physician education regarding the
beneﬁts and optimal monitoring of OAC therapy will lead to lower
Y.-J. Lin, H.L. Po48stroke rates in the future. A specialized anticoagulation clinic may
make it easier for physicians to initiate and maintain safe OAC
therapy in geriatric patients.References
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